Category Archives: Covid-19/2019-nCoV Dr. Lucey Q&A

Key parameters in the Phase 3 Moderna COVID-19 vaccine protocol: Symptomatic infections, interim analyses and an oversight group 

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Moderna and Pfizer-BioNTech on Sept. 17 publicly posted their ongoing Phase 3 efficacy vaccine trials. Initially today for the Moderna trial, some of the key points are emphasized below on how the primary endpoint for vaccine efficacy is defined, and when the two interim analyses are planned. After […]

COVID-19: New EUA guidance in time for Oct. 22 FDA vaccine meeting?

By on .

By Daniel R. Lucey M.D., MPH, FIDSA On Sept. 11 the U.S. Food and Drug Administration Commissioner Dr. Hahn tweeted a link to a five-page FDA document, “The FDA’s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health” in which he states: “The FDA also intends to issue additional guidance shortly to provide sponsors […]

Trick or treat? A fact check on a COVID-19 Vaccine before Halloween

By on .

By Daniel R. Lucey M.D., MPH, FIDSA On August 26, U.S. Food & Drug Administration Commissioner Dr. Stephen Hahn tweeted that the FDA Vaccine Advisory Committee will be convened Oct. 22 to review COVID-19 vaccines. On August 30 Dr. Hahn was reported in the Financial Times stating he would consider issuing an EUA — an […]

WHO website lists nine Phase 3 vaccine candidate protocols around the world

By on .

By Daniel R. Lucey M.D., MPH, FIDSA The World Health Organization updated its website Sept. 9 on COVID-19 vaccine candidates with a line listing of 180 different candidates including 35 in clinical trials and 145 still in pre-clinical stage. Of the 35 vaccine candidates in clinical trials (Phase 1, 2 and/or 3), WHO has listed […]

Phase 3 vaccine trials in the U.S. July 27-Aug. 20/21: A timeline

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Phase 3 COVID-19 vaccine trials in the United States began July 27 with both the Moderna vaccine and the Pfizer/BioNTech vaccine. Given that both vaccine studies are (separately) enrolling 30,000 volunteers (half receive placebo), and given that both require two doses separated by either 28 days (Moderna) or […]

COVID vaccine candidates:  WHO lists 30 in clinical evaluation, six in phase 3 

By on .

By Daniel R. Lucey M.D., MPH, FIDSA Today the World Health Organization updated its DRAFT landscape of COVID-19 candidate vaccines. In a nine-page table format, WHO lists 30 candidate vaccines in clinical evaluation, and 139 candidate vaccines in preclinical evaluation. For all 169 candidate vaccines, information is provided for the name of the developer and […]

COVID-19: Eight key factual statements from Wuhan Institute of Virology’s Dr. Zhengli Shi

By on .

By Daniel R. Lucey M.D., MPH, FIDSA In response to a series of questions asked by Science magazine’s Jon Cohen, the Wuhan Institute of Virology’s internationally-renowned bat coronavirus researcher and collaborator (with scientists in the United States, Singapore, and elsewhere), Dr. Zhengli Shi provided key facts about her work. Among questions she addressed were ones […]

COVID-19: HHS explains “Operation Warp Speed”

By on .

By Daniel R. Lucey M.D., MPH, FIDSA On Friday, The U.S. Department of Health and Human Services posted a succinct 4-page document titled “Explaining Operation Warp Speed.” The summary begins by answering three questions: What is the goal [of OWS]? How will the goal will be accomplished? Who is working on OWS? It moves to […]

COVID-19: FDA Emergency Use Authorization for a vaccine in the fall of 2020 means the time for public dialogue is August      

By on .

By Daniel R. Lucey M.D., MPH, FIDSA The only past U.S. Food and Drug Administration Emergency Use Authorization for any vaccine was in January 2005 for the licensed (since 1970) anthrax vaccine to be used in military personnel “for prevention of inhalation anthrax for individuals between 18 and 65 years of age who are deemed […]

COVID-19: More than 90,000 infections, 500 deaths in U.S. health care personnel

By on .

By Daniel Lucey MD, MPH, FIDSA Today, more somber statistics on the pandemic posted on the U.S. Centers Disease Control COVID-19 website: Since the previous day, 54,357 new cases of SARS-CoV-2 infection were documented (of the total 2,679, 230 US cases in 2020, accordingly to the CDC). Not surprisingly, as the number of hospitalizations is […]